cpu0213 and Shock--Septic

cpu0213 has been researched along with Shock--Septic* in 2 studies

Other Studies

2 other study(ies) available for cpu0213 and Shock--Septic

ArticleYear
Down-regulation of FKBP12.6 and SERCA2a contributes to acute heart failure in septic shock and is related to an up-regulated endothelin signalling pathway.
    The Journal of pharmacy and pharmacology, 2007, Volume: 59, Issue:7

    Acute heart failure (AHF) critically affects morbidity and mortality in patients suffering from septic shock. It is hypothesized that AHF is linked to down-regulation of FKBP12.6 (calstabin 2) and SERCA2a (sarco/endoplasmic reticulum Ca2+ ATPase 2a), which may be mediated by an activated endothelin (ET) system in the myocardium. The aim of the study was to test whether an attenuation of septic AHF can be achieved by a novel dual endothelin receptor antagonist, CPU0213, in association with up-regulation of FKBP12.6 and SERCA2a in rats. AHF in septic shock was produced by faeces leak from a surgically punctured caecum for 72 h in rats. CPU0213 (30 mg kg(-1), s.c., every 12 h, for 3 days) was administered to rats 8 h after the operation. In the untreated model group, survival rate markedly decreased (P < 0.01), and the cardiac performance was seriously compromised (P < 0.01) relative to control. The AHF was characteristically associated with down-regulated mRNA and protein expressions of FKBP12.6, SERCA2a and PLB (phospholamban). Elevated ET-1 and mRNA abundances of the preproET-1, ECE (endothelin converting enzyme) and ET(A) and ET(B) receptors in the left ventricular tissue (P < 0.01) were found. All abnormalities were reversed significantly following CPU0213 administration. In conclusion, septic AHF is attributed to down-regulation of FKBP12.6 and SERCA2a, which is related to an activated ET system. An endothelin receptor antagonism of CPU0213 significantly improves the cardiac performance by blocking both ET(A) and ET(B) receptors.

    Topics: Acute Disease; Animals; Aspartic Acid Endopeptidases; Blotting, Western; Calcium; Calcium-Binding Proteins; Down-Regulation; Endothelin Receptor Antagonists; Endothelin-Converting Enzymes; Heart Failure; Heart Rate; Male; Metalloendopeptidases; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidative Stress; Pyrazoles; Rats; Rats, Wistar; Receptors, Endothelin; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Shock, Septic; Signal Transduction; Tacrolimus Binding Proteins; Up-Regulation; Vasoconstrictor Agents

2007
CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by suppressing ET system and NF-kappaB in rats.
    Acta pharmacologica Sinica, 2006, Volume: 27, Issue:9

    To examine whether a novel endothelin receptor antagonist, CPU0213, is effective in relieving the acute renal failure (ARF) of septic shock by suppressing the activated endothelin-reactive oxygen species (ET-ROS) pathway and nuclear factor kappa B (NF-kappaB).. The cecum was ligated and punctured in rats under anesthesia. CPU0213 (30 mg .kg(-1).d(-1), bid, sc X 3 d) was administered 8 h after surgical operation.. In the untreated septic shock group, the mean arterial pressure and survival rate were markedly decreased (P<0.01), and heart rate, weight index of kidney, serum creatinine and blood urea nitrogen, 24 h urinary protein and creatinine were significantly increased (P<0.01). The levels of ET-1, total NO synthetase (tNOS), indusible nitric oxide synthetase (iNOS), nitric oxide (NO), and ROS in serum and the renal cortex were markedly increased (P<0.01). The upregulation of the mRNA levels of preproET-1, endothelin converting enzyme, ET(A), ET(B), iNOS, and tumor necrosis factor-alpha in the renal cortex was significant (P<0.01). The protein amount of activated NF-kappaB was significantly increased (P<0.01) in comparison with the sham operation group. All of these changes were significantly reversed after CPU0213 administration.. Upregulation of the ET signaling pathway and NF-kappaB play an important role in the ARF of septic shock. Amelioration of renal lesions was achieved by suppressing the ET(A) and ET(B) receptors in the renal cortex following CPU0213 medication.

    Topics: Acute Kidney Injury; Animals; Endothelin Receptor Antagonists; Endothelin-1; Kidney Cortex; Male; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pyrazoles; Rats; Rats, Wistar; Reactive Oxygen Species; RNA, Messenger; Shock, Septic; Tumor Necrosis Factor-alpha

2006